Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,972.8
23.8 (0.81%)

 

  • STI Straits Times Index
    2,972.8
    23.8 (0.81%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,568.6
    -9.2 (-0.58%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    29,452.6
    472.4 (1.63%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,551.4
    42.3 (1.21%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,663.5
    697.5 (2.41%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,338.5
    96.7 (1.55%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,772.7M
  • Value: 1,403.1M
  • Rise: 195
  • Fall: 170
  • Unch: 409

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Oceanus^0.073+0.002
CWX Global0.005-0.002
Thomson Medical0.120+0.001
Jiutian Chemical0.090+0.001
Sembcorp Marine0.153-
YZJ Shipbldg SGD1.080+0.010
Avarga0.330-0.035
Shen Yao0.004-
Jasper Inv0.005-0.001
Secura0.100-0.002

World Indices

World Indices
Name Last Change
Nasdaq 13,192.3 +72.9
HSI 29,452.6 +472.4
HSCEI 11,453.7 +206.5
Jakarta 6,338.5 +96.7
Nikkei 225 29,663.5 +697.5
SSE Comp 3,551.4 +42.3
Shanghai A 3,722.6 +44.4
Shanghai B 246.1 +2.8
KOSPI 3,099.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Suntar Eco-City SUNTAR ECO-CITY LIMITED
Quotes 10 Minutes Delayed. Updated at 01 Mar 2021 07:12
Last (SGD): 0.700 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 0.700
Buy Price 0.700 Sell Price -
Buy Volume ('000) 20.0 Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.00008 Trailing EPS (SGD) e 0.01463 NAV (SGD) b 0.2813
PE a 8750.000 Trailing PE f 47.856 Price / NAV b 2.4884
Dividend (SGD) d - Cash In Hand (SGD) g 0.0736 Issued & Paid-up Shares c 62,760,000
Dividend Yield (%) d - Price / Cash In Hand g 9.511 Treasury Shares h -
Beta - 75 Daysi -0.003 R-Squared - 75 Days(%)i 0.43 Market Cap (M) 43.932
Beta - 500 Daysi -0.236 R-Squared - 500 Days (%)i 0.23 Enterprise Value (M) 31.933
Piotroski F Score 5 Exchange Code BKZ Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 32.8431 6-Month VWAP 0.697 Free Float (%) -
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification China / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 04 Jan 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Suntar Eco-City SGX 43.932 8750.000 47.856 2.4884 -
Industry Biotechnology SGX 2,992.412 4.594 4.591 0.5877 5.582
China SGX 789.145 21.429 49.336 0.8342 3.227
Medical & Biotechnology SGX 965.897 21.066 22.181 1.3947 1.975
Local Peer Lonza SGX 5,940.891 4.560 4.560 0.5844 5.624
Global Peer AMGEN INC NASDAQ 129,906.145 17.884 17.884 13.8066 2.849
Global Peer CSL LTD ASX 119,481.601 38.096 31.395 11.3067 1.118
Global Peer GILEAD SCIENCES INC NASDAQ 77,154.626 627.299 627.273 4.2388 4.421
Global Peer ILLUMINA INC NASDAQ 64,109.919 97.729 97.729 13.6579 -
Global Peer MODERNA INC NASDAQ 61,259.865 - - - -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 55,254.498 20.377 20.377 6.3607 -
Global Peer WUXI BIO HKEx 430,698.345 374.657 299.115 28.8323 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 48,270.452 13.740 13.740 4.3782 -
Global Peer BIOGEN INC NASDAQ 41,569.448 10.391 10.391 3.8849 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 33,581.782 55.654 55.654 2.8823 -
Other Global Peers BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), SEAGEN INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), SINO BIOPHARM (HKEx), 10X GENOMICS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), NOVAVAX INC (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), BIO-TECHNE CORP (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ZAI LAB-SB (HKEx), BRIDGEBIO PHARMA INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), BEAM THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), JOINN (HKEx), CHEMOCENTRYX INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), FIBROGEN INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), ARVINAS INC (NASDAQ), GENSCRIPT BIO (HKEx), RELAY THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ALKERMES PLC (NASDAQ), SEER INC (NASDAQ), VIELA BIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), XENCOR INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), 3SBIO (HKEx), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), LIGAND PHARMACEUTICAL INC (NASDAQ), ALLOVIR INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), NUVATION BIO INC (NYSE), KYMERA THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), OCUGEN INC (NASDAQ), JW THERAP-B (HKEx), JACOBIO-B (HKEx), MYOVANT SCIENCES LTD (NYSE), DICERNA PHARMACEUTICALS INC. (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), BIOATLA INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), TRANSLATE BIO INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), PRECIGEN INC (NASDAQ), VIVA BIOTECH (HKEx), ZENTALIS PHARMACEUTICALS INC (NASDAQ), REGENXBIO INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), UNIQURE N.V. (NASDAQ), ALPHAMAB-B (HKEx), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), NKARTA INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUNOVANT INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), MACROGENICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), FRONTAGE (HKEx), PERSONALIS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), POLYNOVO LIMITED (ASX), JHBP-B (HKEx), VAXCYTE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ASCENTAGE-B (HKEx), ZIOPHARM ONCOLOGY INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MORPHIC HOLDING INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), MESOBLAST LTD (ASX), MIMEDX GROUP INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), VANDA PHARMACE INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), EPIZYME INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), HUMANIGEN INC (NASDAQ), INHIBRX INC (NASDAQ), PASSAGE BIO INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PROTHENA CORP PLC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), KINTOR PHARMA-B (HKEx), RUBIUS THERAPEUTICS INC (NASDAQ), VAXART INC (NASDAQ), CHIMERIX INC (NASDAQ), MERUS B V (NASDAQ), CURIS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), VBI VACCINES INC CDA (NASDAQ), ATHIRA PHARMA INC (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), KADMON HLDGS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), COMPUGEN (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), AKOUOS INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), IMMATICS N V (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), AFFIMED N V (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), MEIRAGTX HOLDINGS PLC (NASDAQ), ATRECA INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), ALTIMMUNE INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ARDELYX INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), GERON CORP (NASDAQ), IVERIC BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), SINOMAB BIO-B (HKEx), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), DPHARMA (Bursa), AKEBIA THERAPEUTICS INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), ADICET BIO INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), BIOVIE INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), ASCLETIS-B (HKEx), SESEN BIO INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), IMMUNOME INC (NASDAQ), OPTHEA LIMITED (ASX), PORTAGE BIOTECH INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), ONCORUS INC (NASDAQ), ATHERSYS INC (NASDAQ), XOMA CORP (NASDAQ), VERASTEM INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), IMUGENE LIMITED (ASX), FORTE BIOSCIENCES INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ESSEX BIO-TECH (HKEx), LINEAGE CELL THERAPEUTICS INC (NYSE American), SURFACE ONCOLOGY INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), PARATEK PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ANTEOTECH LIMITED (ASX), 9 METERS BIOPHARMA INC (NASDAQ), TREVENA INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), KAMADA LTD (NASDAQ), MEDICINOVA INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), NANOVIRICIDES INC (NYSE American), LARIMAR THERAPEUTICS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CHIASMA INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), IMV INC (NASDAQ), METACRINE INC (NASDAQ), BIONOMICS LTD (ASX), ADMA BIOLOGICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), AXCELLA HEALTH INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), EQUILLIUM INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), NEXT SCIENCE LTD (ASX), CATALYST BIOSCIENCES INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), IMMUTEP LTD (ASX), ENOCHIAN BIOSCIENCES INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CEL-SCI CORP (NYSE American), IDERA PHARMACEUTICALS INC (NASDAQ), IBIO INC (NYSE American), AZIYO BIOLOGICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ORGENESIS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), LONGEVERON INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), ENZO BIOCHEM INC (NYSE), LEAP THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), SYNLOGIC INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), GALECTIN THERAPEUTICS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), AIKIDO PHARMA INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), DIFFUSION PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), LUMOS PHARMA INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), CIDARA THERAPEUTICS INC (NASDAQ), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), INFLARX N V (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ADVAXIS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), COHBAR INC (NASDAQ), SAVARA INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), ORGANOVO HLDGS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), LEAF RESOURCES LTD (ASX), VASCULAR BIOGENICS LTD (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), WINDTREE THERAPEUTICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), UNI-BIO GROUP (HKEx), MONOPAR THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CHIMERIC THERAPEUTICS LTD (ASX), AZURRX BIOPHARMA INC (NASDAQ), REGENT PACIFIC (HKEx), CYNATA THERAPEUTICS LTD (ASX), GENETIC TECHNOLOGIES (ASX), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), PLUS THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), MEMPHASYS LTD (ASX), CATABASIS PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), KIROMIC BIOPHARMA INC (NASDAQ), SOLIGENIX INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), NABRIVA THERAPEUTICS PLC (NASDAQ), ORAGENICS INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CT ENTERPRISE (HKEx), BIO-PATH HOLDINGS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), PRECIPIO INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), BIOTRON (ASX), CYCLACEL PHARMACEUTICALS INC (NASDAQ), PATRYS LIMITED (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ADALTA LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), HISTOGEN INC (NASDAQ), GEOVAX LABS INC (NASDAQ), INMED PHARMACEUTICALS INC (NASDAQ), CONSTELLATION TECHNOLOGIES LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), REGENEUS LTD (ASX), RHINOMED LIMITED (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), BELLICUM PHARMACEUTICALS (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), BRIACELL THERAPEUTICS CORP (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENESTECH INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), BENITEC BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), NANOLLOSE LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), CRYOSITE (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days ---
Medium Term Return 3 Months -+0.005
+0.72 %
6 Months ---
1 Year -+0.405
+137.29 %
Long Term Return 2 Years -+0.580
+483.33 %
3 Years -+0.530
+311.76 %
5 Years -+0.200
+40.00 %
Annualised Return Annualised --
+6.96 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.295 - 0.700 Change From 1 Year Low +0.405 % Change From 1 Year Low (%) +137.29
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 0.100 - 0.700 Change From 2 Years Low +0.600 % Change From 2 Years Low (%) +600.00
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 0.100 - 0.700 Change From 5 Years Low +0.600 % Change From 5 Years Low (%) +600.00
Change From 5 Years High - % Change From 5 Years High (%) -
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 22 September 2006 as a private limited company under the name Reyphon Agriceutical Pte Ltd. The Company was renamed to Reyphon Agriceutical Limited on 13 July 2007.
The Group's principal products are gibberellic acids, a plant growth regulator, and validamycin, a plant antibiotic. The Group also possess the know-how to produce fermentation-based pesticides. Its main product, gibberellic acids, is used in China mainly in the cultivation of hybrid rice, cotton, fruits and vegetables. Through active R&D, its objective is to widen the applications of gibberellic acids to cultivation of other plants such as tea plants, peanuts and soybean and lower its production costs and offer customers greater value with our gibberellic acids products.The Group manufactured, agriceutical products may be broadly classified into the following categories:-
(a) plant growth regulators;
(b) pesticides which include plant antibiotics, insecticide and weedicides; and
(c) fertilisers.

Its production facilities are located in Southern Industrial Development Zone of Xin?gan County, Jiangxi Province of China on a land area of approximately 65,002 sq m. Its products are sold throughout China such as Zhejiang, Fujian, Guangdong, Guangxi, Yunnan, Jiangsu, Shangdong, Hebei, Xinjiang, Anhui, Hainan, Hunan, Sichuan and Hubei. The Group also exports its products to countries such as United States, India, Turkey, Belgium, Canada, Germany, Malaysia, Pakistan, Spain, United Kingdom and Vietnam.

Change of Name:
Reyphon Agriceutical Limited to Suntar Eco-City Limited. Trading under the new name wef 14 June 2012.

Current core business of the Group has hereby expanded to include the eco-tourism real estate development and management business.

IPO Performance

Listing Date 01 Aug 2007 Full Subscription Rate (x) 13.55
No of Placement Shares (M) 76.60 No of Public Offer Shares (M) 2.00 Public Offer Subscription Rate (x) 494.05
IPO Price (SGD) a 1.950 First Day Close (SGD) a 3.050 First Week Close (SGD) a 2.500
Current vs IPO Price (%) -64.10 First Day Gain (%) +56.41 First Week Gain (%) +28.21
Notes:
  1. Adjusted for the following: Share Consolidation 1 for 5 on 19/11/2015

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Dec 2019 Part 1(1.45 MB)
Annual Report 2018 Dec 2018 Part 1(3.17 MB)
Annual Report 2017 Dec 2017 Part 1(4.01 MB)
Annual Report 2016 Dec 2016 Part 1(1.06 MB)
Annual Report 2015 Dec 2015 Part 1(1.97 MB)
Annual Report 2014 Dec 2014 Part 1(1.50 MB)
Annual Report 2013 Dec 2013 Part 1(0.95 MB)
Annual Report 2012 Dec 2012 Part 1(0.51 MB)
Annual Report 2011 Dec 2011 Part 1(0.64 MB)
Annual Report 2010 Dec 2010 Part 1(0.85 MB)
Annual Report 2009 Dec 2009 Part 1(0.98 MB)
Annual Report 2008 Dec 2008 Part 1(1.53 MB)
Annual Report 2007 Dec 2007 Part 1(1.61 MB)
IPO Prospectus
IPO Prospectus 2007 Jul 2007 Part 1(3.22 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
26 Feb 2021 0.700 0.700 0.700 0.700 - -
25 Feb 2021 0.700 0.700 0.700 0.700 - -
24 Feb 2021 0.700 0.700 0.700 0.700 - -
23 Feb 2021 0.700 0.700 0.700 0.700 - -
22 Feb 2021 0.700 0.700 0.700 0.700 - -
19 Feb 2021 0.700 0.700 0.700 0.700 - -
18 Feb 2021 0.700 0.700 0.700 0.700 - -
17 Feb 2021 0.700 0.700 0.700 0.700 - -
16 Feb 2021 0.700 0.700 0.700 0.700 - -
15 Feb 2021 0.700 0.700 0.700 0.700 - -
11 Feb 2021 0.700 0.700 0.700 0.700 - -
10 Feb 2021 0.700 0.700 0.700 0.700 - -
09 Feb 2021 0.700 0.700 0.700 0.700 - -
08 Feb 2021 0.700 0.700 0.700 0.700 - -
05 Feb 2021 0.700 0.700 0.700 0.700 - -
04 Feb 2021 0.700 0.700 0.700 0.700 4,200 0.7000
03 Feb 2021 0.700 0.700 0.700 0.700 - -
02 Feb 2021 0.700 0.700 0.700 0.700 - -
01 Feb 2021 0.700 0.700 0.700 0.700 - -
29 Jan 2021 0.700 0.700 0.700 0.700 - -
28 Jan 2021 0.700 0.700 0.700 0.700 - -
27 Jan 2021 0.700 0.700 0.700 0.700 - -
Summary
Current 2 Weeks
(15 Feb 2021 to 26 Feb 2021)
0.700 0.700 0.700 0.700 - -
Previous 2 Weeks
(29 Jan 2021 to 11 Feb 2021)
0.700 0.700 0.700 0.700 4,200 -
4 Weeks from
(31 Dec 2020 to 28 Jan 2021)
0.695 0.700 0.695 0.700 15,800 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.